Roche Diagnostics Hit By China Reforms As Q1 Sales Remain Flat

Despite Healthcare Pricing Reforms And Volume-Based Procurement, Roche Views China As Critical Market

 
• By Shubham Singh
  
Roche attributed the stagnation to significant pricing pressures stemming from China’s healthcare reform agenda, including an expansion of volume-based procurement (VBP) programs. (Shutterstock)

More from Diagnostics

More from Business